Aquestive Therapeutics AQST announced that the FDA has informed that no advisory committee meeting is required to discuss the new drug application (NDA) for AQST’s key product candidate, Anaphylm ...
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Aquestive Therapeutics (AQST) one of those stocks right now? By taking a look at ...
The U.S. Food and Drug Administration (FDA) on Thursday informed Aquestive Therapeutics, Inc. (NASDAQ:AQST) that an advisory committee meeting is not required for Anaphylm (dibutepinephrine) ...
We recently published a list of 10 Best Multibagger Stocks To Buy Heading into 2025. In this article, we are going to take a look at where Aquestive Therapeutics, Inc. (NASDAQ:AQST) stands against ...
The company also collaborates with pharmaceutical companies to bring new molecules to market using its technologies, like PharmFilm. Aquestive is advancing a late-stage proprietary product candidate ...
Detailed price information for Aquestive Therapeutics Inc (AQST-Q) from The Globe and Mail including charting and trades.
Hosted on MSN
Why did AQST stock plunge 40% in pre-market today?
Shares of Aquestive Therapeutics (AQST) plunged 40% in pre-market trading on Friday after the company announced that it received a letter from the U.S. Food and Drug Administration (FDA) identifying ...
Aquestive Therapeutics: Robust Development Of Oral Emergency Therapies Will Likely Pay Off Into 2025
Aquestive Therapeutics shares surged 137.29% (YoY) after FDA approval of rival company ARS Pharmaceutical's "epinephrine nasal spray" Neffy. Market optimism surrounds AQST’s robust R&D pipeline, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results